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Abstract
Background: Proton Magnetic Resonance (MR) Spectroscopy (MRS) is a widely available technique for those
clinical centres equipped with MR scanners. Unlike the rest of MR-based techniques, MRS yields not images but
spectra of metabolites in the tissues. In pathological situations, the MRS profile changes and this has been
particularly described for brain tumours. However, radiologists are frequently not familiar to the interpretation of
MRS data and for this reason, the usefulness of decision-support systems (DSS) in MRS data analysis has been
explored.
Results: This work presents the INTERPRET DSS version 3.0, analysing the improvements made from its first release
in 2002. Version 3.0 is aimed to be a program that 1st, can be easily used with any new case from any MR scanner
manufacturer and 2nd, improves the initial analysis capabilities of the first version. The main improvements are an
embedded database, user accounts, more diagnostic discrimination capabilities and the possibility to analyse data
acquired under additional data acquisition conditions. Other improvements include a customisable graphical user
interface (GUI). Most diagnostic problems included have been addressed through a pattern-recognition based
approach, in which classifiers based on linear discriminant analysis (LDA) were trained and tested.
Conclusions: The INTERPRET DSS 3.0 allows radiologists, medical physicists, biochemists or, generally speaking, any
person with a minimum knowledge of what an MR spectrum is, to enter their own SV raw data, acquired at 1.5 T,
and to analyse them. The system is expected to help in the categorisation of MR Spectra from abnormal brain
masses.
Background
The diagnosis of an abnormal brain mass usually
depends on the histopathological analysis of a brain
biopsy, since imaging techniques can only correctly
characterize the type and grade of a tumour in a few
instances [1]. Proton magnetic resonance spectroscopy
(1H-MRS) is one of several MR-based techniques, which
gives information about metabolites in solution in the
millimolar range of concentration, in living tissues. The
MR spectroscopic pattern has been shown to be
characteristic of certain tumour types, but since there is
no specific marker signal for type or grade and several
signals change at a time in pathological conditions.
Therefore, the need for a multivariate analysis of the
MR spectrum for diagnostic or prognostic purposes has
been pursued for nearly two decades [2,3]. The INTER-
PRET project [4] successfully developed a program for
brain tumour characterisation with the use of 1H-MRS
data: it was named “INTERPRET decision-support sys-
tem (DSS)”. It involved the accrual of a large number of
MRS data from brain tumour patients, the creation of a
database [5], the training of a mathematical classifier [6]
and finally, the introduction of both data and classifiers
into the final program. The performance of the MR
spectrometers of INTERPRET participants was assessed
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bimonthly by a short protocol that used a dedicated
phantom [7]. After the end of the project, the DSS
started to be distributed free of charge through the pro-
ject’s web page http://gabrmn.uab.es/INTERPRET. How-
ever, it presented several practical limitations with
respect to its routine use at radiology facilities. First of
all, since database development, population and DSS
development had been performed in parallel, the final
system did not benefit from the extensive data quality
controls applied to the database [5], and therefore the
DSS contained small errors. The most important limita-
tions still, were the lack of connection between the data
processing that is always needed with MRS data and the
introduction of new cases of unknown pathology for
their evaluation. Therefore, the system in its first version
could only be used for demonstration purposes or as an
MRS learning tool, but not as one that allowed users to
enter a new, unprocessed MR spectrum from any format
or manufacturer and to evaluate it with the system.
This paper explains the path followed from 2003 to
2010, from the first release of the system to the current
3.0, to turn the DSS into a program that 1st, can be
easily used with any new case from any MR scanner
manufacturer and 2nd, improves the initial analysis cap-
abilities of the first version.
Implementation
Data types stored
The system can store the following data types for each
case:
-Processed Single Voxel (SV) MR Spectra acquired at
1.5 T, at short (20-32 ms) and long (135-144 ms) TE,
including information on TE, TR and acquisition
sequence (PRESS or STEAM).
-MRI (T1-W (weighted), T2-W, proton density (PDW)
and volume of interest (VOI) images). Accepted formats
are jpg, bmp and DICOM http://medical.nema.org/,
which are displayed with ImageJ http://rsbweb.nih.gov/ij
working in the background.
-Clinical information (Clinical Record, CR) [4]: Age,
Sex, Tumour Location, Tumour Size, Radiological Diag-
nosis, Total Tumour Removal, Subtotal Tumour
Removal, Stereotactic Biopsy, Paraffin Section WHO
Classification [8], Daumas-Duport Astrocytoma Grade
[9], Outcome Score at Three Months, Outcome Score at
Two Years, Concomitant Disease, Histopathology Vali-
dated, Localisation Validated and Assigned Class.
-Case notes.
All cases included were acquired with INTERPRET-
compatible acquisition protocols [4].
The term “tissue type” is used instead of the terms
“tumour class” or “disease”, since the system was
designed to handle not only distinctions among different
tumour types but also between diseases or regions of
the brain (such as normal non-affected brain or diseased
brain).
Database
Version 3.0 comes with an embedded database devel-
oped in SQL over the standalone HSQLDB database
engine http://www.hsqldb.org. The database stores not
only the cases and their related information but also
classifier information, users’ profiles and their customi-
sations. Figure 1 shows the entity-relationship (E-R) dia-
gram of the database.
The data manipulation software
The Data Manipulation Software (DMS) was incorpo-
rated into the INTERPRET DSS on version 2.0. It is an
MR spectra-processing tool developed during INTER-
PRET (2000-2002) with a set of routines from mMRUI
http://sermn02.uab.cat/mrui which, 1st) automates the
MR spectra processing procedure and 2nd) generates
what is called the “INTERPRET canonical format” or
DMS format, which allows multi-scanner, multi-format
spectral analysis [4]. This constitutes a relevant feature
since different scanner manufacturers provide different
number of points and sweep widths (range of frequen-
cies covered), yielding variable spectral resolutions
(points/ppm).
Since 2002, the range of formats available in the radi-
ological environment increased, especially for General
Electric (GE), which is now on 15.x and 20.x versions
depending on the countries. The DMS is only able of
reading up to 6.x GE Probe raw data files and 8.x and 9.
x Probe raw data files provided that they carry a SAGE
Header companion file (SHF) and the .7 suffix is elimi-
nated. To our knowledge, in 2010 the DMS can still
perform the whole pipeline (from format reading to
delivery of the automatically processed and aligned spec-
trum) for Philips raw data files.
Therefore, it was necessary to find a workaround for
the problem of reading new vendor formats, and the
Java based DMS (JDMS) was developed to this end.
With the JDMS, the JMRUI program [10,11] can be
used as a format converter. The user can open his/her
raw data file and save it as text file without carrying out
any processing. This is especially important for those
raw data files from multi-channel coils where the files
have to be manually consolidated in order to obtain a
single acquisition file. In that case, each file (one for
metabolites, one for water signals) has to be saved after
adding all corresponding acquisitions, in text format
with *.txt extension using the JMRUI. Finally, in acquisi-
tions for which the automatic processing does not pro-
vide a satisfactorily aligned or phased spectrum, the user
is encouraged to use JMRUI and the JDMS as well. In
these cases, spectra should be processed with JMRUI
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Figure 1 E-R diagram of the embedded database. The database stores Users’ profiles, Cases’ data and Classifiers’ data. The “User” table
handles usernames and passwords, as well as administration rights. The “Case” table depends from the “User” table and stores the disease type,
case ID and where the information objects are stored. There are three dependent tables, Spectrum, Clinical Record and Tumour type, which
store information related to acquisition parameters and MR spectra file formats, clinical information and the list of possible diseases, respectively.
Finally, the Classifier table handles which classifier and echo times the system has to choose for display. The Classifier variable table stores × and
Y positions of each case in the 2D plot, according to the classifiers selected.
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using the same processing parameters used by the DMS,
with minor zero or first order phasing and saved as
JMRUI txt files. When these files are entered into the
system, the embedded JDMS will automatically convert
them into the DSS format. The processing parameters
are fully described in the Help section of the software.
Figure 2 summarises the different paths for processing
raw data files to obtain a file in the DMS format.
The DMS format has 512 points to represent the
range between 7.1 to -2.7 ppm http://gabrmn.uab.es/
dms. It has the “art” extension and is a simple ASCII
text file with real numbers (simple precision) separated
by spaces, where the first point corresponds to the spec-
tral intensity at 7.1 ppm.
The automatic processing performed by the DMS is
essentially similar to what was already described in [4],
with the following improvements:
1. Water filtering using HLSVD [12] with 10 lorent-
zians instead of 5.
2. Line broadening of 1 Hz instead of 0.8 Hz.
3. Baseline offset corrected taking into account both
sides of the water peak (-2 to -1 ppm and 9 to 11 ppm).
4. Linear interpolation, for those file formats with an
unequal number of points in the [7.1, -2.7] ppm interval
with respect to Philips files [4].
5. Alignment: The alignment process adds zeros to the
beginning or to the end of the spectrum and removes the
same number of data points in the opposite side, in order
to move the desired peak to the expected position. Align-
ment is based on the algorithm shown in Figure 3 and it
searches, in this order, for the Creatine peak, the Cho-
line-containing compounds peak, and the Lipid peaks, at
3.03, 3.21, and 1.29 ppm respectively. Each peak is
searched in a range near the expected position (± 4 or 5
data points). A point will be considered a peak only if its
intensity value is greater than the value of the contiguous
points on its left and right sides. If none of these three
peaks is found in the ranges expected, the spectrum can-
not be automatically aligned and is left unchanged.
The DMS is distributed as well as an independent
software module http://gabrmn.uab.es/dms.
Case sets
The availability of an embedded database in version 3.0
allowed the inclusion of more than one case set.
Four different case sets are therefore available: 1) The
INTERPRET cases, 2) The IDI-Bellvitge cases, 3) Exam-
ple cases and, 4) User cases. If available, for each case
set, it is possible to have the short TE spectrum, the
long TE spectrum and the concatenated short+long TE
spectra as in [13]. In addition, the four sets of cases can
be displayed with any of the classifiers, one or all four at
a time. A short description of each set follows below:
1) Cases from the INTERPRET database [5], checked
for quality control and reprocessed with the DMS or
JMRUI plus JDMS if necessary (for a detailed list of
Figure 2 Obtaining processed MRS data in the DMS format. There are two ways to obtain the processed MRS data, manually processing
them with jMRUI or with the DMS. The operation is divided in two steps: preprocessing and processing. Preprocessing identifies the format and
converts files to a canonical raw format that is subsequently processed by the DMS. The DMS can read some formats and in that case
processing is automatic. If the format is not readable, then jMRUI should be used, either for performing the preprocessing or the processing.
There are the jMRUI to canonical raw format (jMRUI2fid) and the jMRUI to DMS converter (jmrui2DMS).
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which cases had been processed with the DMS or with
JMRUI+JDMS, see the program’s help). The case num-
bers and the superclasses they belong to are shown on
Table 1. Note that for the INTERPRET set, two types of
cases are available, those used to train the classifiers
(Most common tumour types, 217 cases at short TE
and 195 cases at long TE and at short+long TE) and
those from the database which belong to other, less
common classes (87 cases at short TE and 71 cases at
long TE or short and long TE).
2) Cases from the Institut de Diagnòstic per la Imatge of
the Bellvitge Hospital (IDI-Bellvitge) from Barcelona,
Spain used in the [14] study, plus 5 normal volunteer
cases from the same centre, obtained in the context of
INTERPRET [4]. The distribution of cases is shown on
Table 1. All these cases come with short and long TE MR
spectra and without any other clinical or MRI information,
except for the definitive diagnosis that is indeed included.
Inclusion criteria for that study were 1) presence of an
untreated, solid, nonnecrotic brain mass suggesting a
brain tumour, 2) diagnosis of pseudotumour or glial
tumor grades II or III of the WHO confidently established,
3) spectra available obtained at both short and long TE,
and 4) the spectra of good quality at visual inspection. The
diagnosis of pseudotumour was based on clinical and ima-
ging follow-up. From a clinical stand-point, patients had
an acute to subacute onset of signs or symptoms involving
a focal neurologic deficit mimicking the findings of an
intracranial neoplasm. Imaging follow-up ranged between
2 and 77 months and showed reduction or resolution of
the mass. The diagnosis of brain tumour was considered
to be confidently established when a sample of the tumor
could be evaluated and the pathologist could establish a
single diagnosis. Histology slides were not circulated to
consulting pathologists like in INTERPRET.
3) Two example cases are available for user practice.
These come from the INTERPRET project as well but
had not been used for classifier development.
4) New cases can be added through the “Load New
Case” option in the “User Cases” menu on top of the
Figure 3 Alignment algorithm. The system searches for the tallest peak (TP) in the 0-4.5 ppm range and for the three important peaks, in this
order: Creatine, Choline and Lipid. If the SNR of the interesting peak is lower than five times the SNR of the TP, then the following peak is
analysed in order to be chosen as reference. At the end, if one of the peaks is the chosen one for alignment, the spectrum is aligned and the
process is terminated, otherwise the spectrum is left unchanged.
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screen. If the user stores them into the database, they
become “User Cases”. All users in the centre using the
same DSS installation can see them but the uploader is
the only user allowed to edit them. This set is initially
void after the DSS installation.
Quality control of data for classification
All information related to INTERPRET cases was
checked for consistency (See “Access to the INTER-
PRET-validated database” link in http://gabrmn.uab.es/
INTERPRET).
MRS data: This is an especially sensitive issue, since the
MR spectra processing protocol might affect classification.
Previously to classification, each case was processed with
the DMS wherever possible and after that, it was individu-
ally checked by expert spectroscopists for alignment and
phasing. For each case in the INTERPRET set, classifica-
tion was performed using the MRS data and their histo-
pathological diagnoses, which were counterchecked
against the INTERPRET database [5]. After inclusion of
each dataset in the GUI, a quality assurance protocol as in
[5] was performed to ensure traceability of the INTER-
PRET dataset in the DSS to the INTERPRET database.
When available, MRI and clinical information were
checked as well. All cases were also checked for quality
control parameters (signal-to-noise (SNR) > 10 and water
linewidth < 8 Hz as computed in [4]) reprocessed with the
DMS or JMRUI plus JDMS if necessary (old cases dating
from the 1990’s period, in which there was no unsup-
pressed water file available, and those in which it was
necessary to perform a minor phasing adjustment).
MRI and clinical data: A quality assurance protocol as
in [5], was followed for the release of version 1.1, check-
ing against the INTERPRET database for MRI and clini-
cal data correctness.
Available classifiers
In its current version 3.0, two abnormal brain mass clas-
sification problems are addressed. The system handles
data at short TE (20-32 ms), long (135-144 ms) and
concatenated short and long TE spectra [13]. One of the
most commonly changed parameters in clinical MR
spectroscopy is echo time (TE), since it can give differ-
ent information about the metabolites contributing to
the spectral pattern and hence, affect the classification
problem addressed [15-17].
The two abnormal brain mass classification problems
addressed are summarised below and on Table 1:
A) Distinction among most common tumour types
(MCTT), as in the original INTERPRET DSS [4]. The
classifiers were trained with the following brain tumour
superclasses: low-grade meningiomas, low-grade glial
tumours (astrocytomas, oligodendrogliomas and oligoas-
trocytomas of WHO grade II) and high-grade aggressive
tumours (glioblastomas and metastases). Three different
classifiers are available, i.e. short, long and concatenated
short+long TE. The classifiers are based on linear discri-
minant analysis (LDA).
B) Distinction between tumour and pseudotumoural
disease (T vs. PS).
B1) Classifies among pseudotumoural disease, tumours
and normal brain tissue. The individual diagnoses
Table 1 DSS 3.0 Datasets (number of cases) and classifiers they served to train
Superclasses used for training the classifiers
Dataset Spectra available Classification Meningioma Aggressive Low-grade
glial




INTERPRET Short TE (20-32 ms) MCTT LDA 58 124 35 217 87 304
Long TE (135-144 ms) MCTT LDA 55 109 31 195 71 266






IDI-Bellvitge Short TE (30 ms) T vs.PS LDA 19 46 5 70 0 70
Long TE (135 ms) T vs.PS LDA 19 46 5 70 0 70
Short + Long TE T vs.PS LDA and
Ratios[14]
19 46 5 70 0 70
Specifications of the two main datasets included in the system, the INTERPRET and the IDI-Bellvitge dataset. Each dataset has short and long TE spectra and both
short and long TE spectra concatenated. Different classification problems have been analysed with these datasets. Furthermore, in the IDI-Bellvitge dataset, the
same classification problem has been solved in two different ways, either by an LDA classification or by a peak height ratio-based classifier [14]. The INTERPRET
dataset contains cases used for training the classifiers as well as from other less common types of tumours. Note that for INTERPRET the number of cases
available at short and long TE is different. MCTT: Most common tumour types; T vs.PS: Tumour vs. pseudotumoural disease. See [4,13] for further details on
superclass definition.
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available are, for pseudotumoural disease, Acute Infarct,
Multiple Sclerosis, Acute Disseminated Encephalomyeli-
tis, and “Non Specific Pseudotumoural Disease"; for
tumoural disease, Astrocytoma WHO grade II, Oligo-
dendroglioma WHO grade II, Oligoastrocytoma WHO
grade II, Astrocytoma WHO grade III, Oligoastrocytoma
WHO grade III. Normal brain tissue cases were taken
from the INTERPRET project [5] (healthy volunteers).
The INTERPRET protocol requested that for normal
volunteer spectra the volume of interest was selected
just above the ventricles in such a way that it contained
mostly white matter avoiding grey matter and cerebral
spinal fluid [7], obtaining a mean spectral pattern for all
volunteers corresponding to the expected for normal
white matter [7].
Three different LDA-based classifiers are available, i.e.
short, long and concatenated short+long TE.. Data used
were single-centre retrospective, and are described in
[14].
B2) Another classifier option addresses the same pro-
blem with the same cases set, but with a ratio-based
decision rule based on peak heights. A graph based in
the Choline/N-acetyl Aspartate ratio at short TE vs. the
m-Inositol/N-acetyl Aspartate at long TE is used
according to [14].
The six LDA-based classifiers were developed with the
“SpectraClassifier” software (http://gabrmn.uab.es/sc,
[18]). Relevant features were selected in the 4.05 - 0.01
ppm range using the Sequential Forward method. Fea-
tures were validated using the correlation-based criter-
ion. Classification was performed with Fisher Linear
Discriminant Analysis and evaluation was performed
with the bootstrap method. The optimum number of
features was selected following criteria described in [19]
and the use of an independent test set.
For the MCTT classifiers, the test set consisted in an
independent set from three medical centres: Centre
Diagnòstic Pedralbes (CDP), Institut d’Alta Tecnologia
(IAT) and Institut de Diagnòstic per la Imatge (IDI)-
Badalona in Barcelona, Spain (data not available with
the software), processed in the same conditions as
above. The test set used was composed of 63 short and
long TE spectra: 3 low-grade meningiomas, 20 low-
grade glial tumours and 40 high-grade aggressive
tumours. For the T vs. PS classifiers, the test set was the
same as in [14]. Table 2 shows the classification results
for all the classifiers included in the different releases.
Overview of the graphical user interface (GUI)
The INTERPRET DSS 3.0 preserves the layout of the
first release. Figure 4 shows the system GUI, which is
divided into two parts: The left side is the database
explorer “Overview Panel” and the right side is the case
explorer. The “Overview Panel” shows cases included
into the embedded database, grouped by case sets and
by tissue type or superclass. The right side is used to
display individual cases, and two “Data Inspection
Panels” are provided (top and bottom).
The first version only contained one case set (the
INTERPRET dataset with spectra at short TE) and one
classifier (for discriminating the most common tumour
types at short TE [4]). Now, users can select one out of
several classifiers through the top menu provided. When
a classifier is selected, the left side adopts a predefined
configuration that shows only the cases used to develop
the classifier selected. Users can also select which case
sets and classes will be shown in the “Overview Panel”,
with the help of the options provided in the “Option
Panel” placed below it. The “Overview Panel” is a 2D
scatter-plot of cases where each case is represented by a
glyph. Cases are spatially positioned according to the
selected classifier. The shape and colour of each glyph is
fully customizable, and they represent the grouping cri-
teria (classes, superclasses or tissue types). The cross
indicates the position of the class, superclass or average
pattern of the tissue type in a specific classifier.
The background colour of the “Overview Panel” is
always the same, regardless of the classifier chosen.
Table 2 Classification results of the LDA-based classifiers included in the different versions of the INTERPRET DSS
Version Classifier TE Accuracy with training set Classifier tested
with a test set
Number of cases in
the test set
Accuracy with test set
1.1 MCTT Short 94.00% yes 87 85.05%
2.0 MCTT Short 88.94% no - -
2.0 MCTT Long 82.56% no - -
3.0 MCTT Short 89.00% yes 63 82.54%
3.0 MCTT Long 84.20% yes 63 69.84%
3.0 MCTT Short+Long 89.20% yes 63 82.54%
3.0 T vs.PS Short 85.50% yes 19 78.95%
3.0 T vs.PS Long 81.10% yes 19 84.21%
3.0 T vs.PS Short+Long 92.10% yes 19 78.95%
MCTT: Most common tumour types; T vs.PS: Tumour vs. pseudotumoural disease. Summary of classifiers released.
Pérez-Ruiz et al. BMC Bioinformatics 2010, 11:581
http://www.biomedcentral.com/1471-2105/11/581
Page 7 of 12
However, this colour can apparently change when the
user chooses the “Show Boundaries” option from the
popup menu. Choosing this option forces the panel to
show the regions defined by the classifier boundaries.
Each region is drawn with a predefined colour but can
also be customised with the small buttons placed at the
left side of the superclass name or the tissue type name
in the respective tab of the “Options Panel”.
The top menu “Classif:” allows not only to choose a
classifier, but also to make a personalised overview, with
the use of the “Make your own overview” option. Its lay-
out has changed slightly in the last version and now
there is a combo box. When selecting the “Make your
own Overview” option, the user has to choose first if
he/she wants to make a personalised overview based on
short or on long TE spectra. After that, the ppm fea-
tures can be selected (with the sliders provided) for
creating a 2D display of peak heights or peak height
ratios. Note that in order to avoid the “division by zero”
error, when the user selects the ratios option, and with
the purpose of improving the display of all cases in a
set, the minimum value of all spectra in the chosen
dataset is used as offset in order to turn positive all
points in the spectra. The offset is dynamically recalcu-
lated in case of need (e.g. a new case). In this respect,
the user should be aware that this might produce unex-
pected ratio plots when dealing with datasets at long TE
with strong inverted lactate or alanine peaks.
Users can review cases in detail through the two “Data
Inspection Panels” provided. MR spectra, MRI, CR and
notes associated to the selected case can be examined
using the respective tabs.
Intended use
The user is expected to enter a new case formed by a
1.5 T SV MRS set (preferably one short and one long
TE spectrum) from a patient with an abnormal brain
mass, obtained under INTERPRET-compatible acquisi-
tion conditions [4]. After entering the new case into the
system, the DSS is to be used as an analysis tool for the
SV MRS set. The analysis is expected to be performed
using all the system capabilities, 1st) Selection of a clas-
sifier depending on the clinical question that the user
may have, 2nd) Position of the SV MR spectrum in the
“Overview Panel” of the classifier/s selected, 3rd) Analy-
sis of the spectral pattern with the help of the two “Data
Inspection Panels” provided, through comparison of the
problem spectrum with neighbouring cases from the
“Overview Panel” and 4th) Decision whether to perma-
nently store the case or not. The ability to store a case
is a new feature of the DSS and the user is able to study
every new case through different executions of the pro-
gram. The uploader will be able to edit any stored case
at any time.
Inserting additional classifiers and datasets into the
system
Before a new classifier can be used in the DSS, it should
be tailored to maintain the DSS look and feel. Charac-
teristics like aspect ratio (width/height ratio), colours,
Figure 4 INTERPRET DSS GUI. The GUI maintains the same four parts since its first release. The Menu is located on top of the window and
allows entering and managing both cases and users. There are four panels, which are now fully resizable. The Overview Panel, which is on the
left side of the GUI, allows exploring the cases (coloured glyphs) that are distributed in a 2-D plot. The Options Panel is located below the
Overview Panel and serves to customise the classifier classes, the available tissues or tumour classes and the cases sets, as well as the glyphs
colours and sizes. The Top and Bottom Inspection Panels, on the right side, allow the user to examine two MR spectra and to visually compare
them, and also to visually compare with mean and standard deviation plots for any of the classes of the chosen classifier
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names and so on can be customised with the tools
included in the software called SC2DSS (Figure 5).
SC2DSS is only available to the developers’ team
dss@gabrmn.uab.es and it allows to tailor and upload a
new classifier into the INTERPRET DSS. Once a new
classifier is developed the users will receive a new ver-
sion of the database without having to download the
whole DSS system again. This application can populate
the embedded database with the dataset used to develop
the classifier, taking into account the superclasses
defined to create each classifier, the groups of tissue
types and their names. Moreover, SC2DSS inserts the
mathematical representations of the classifier and
the classification boundaries represented by lines into
the DSS-embedded database. In all previous DSS ver-
sions, boundaries between regions defined by classes
were not those defined by classifiers, but the bisectors
between the centroids of each class on display. For LDA
classifiers on Version 3.0, the true boundaries defined
by the LDA classifiers are displayed.
Results
Versions released
DSS development followed several steps in the 2003-
2009 period until version 3.0, with emphasis in two
different aspects: the quality control of the dataset and
the improvements in the GUI.
Version 1. Released in December 2002. It is the initial
development described in [4].
Version 1.1. Released in June 2004. The changes with
respect to previous versions were:
1. Update of all information (clinical and spectro-
scopic) contained in the prototype, according to [5].
In this version, the DMS was still not embedded but
the processing pipeline was refined to its current
state. Baseline correction and automated alignment
were implemented. A final quality assurance step
was also performed to ensure correct migration of
clinical and spectral data from the database to the
prototype.
2. Retrained classifier at short TE, according to [4],
with the updated information.
3. The classifier was tested with an independent set
of 87 cases (12 low-grade gliomas, 58 aggressive
tumours-glioblastomas and metastases- and 17 low-
grade meningiomas) [18].
Version 1.2. Released in November 2004 [20]. In this,
the DCM images were incorporated and an additional
quality assessment on all images was performed.
Figure 5 The SC2DSS tool. The module is divided in two panels, right and left. The right panel corresponds to the desired look-and-feel of the
Overview Panel in the DSS 3.0 GUI. The left panel allows the developer to perform the visual tuning actions to fit the 2-D latent space of each
classifier into the Overview Panel in the GUI. Three features can be tuned, the latent space can be horizontally or vertically flipped with the
“Mirror” function (top right panel). It can also be rotated ("Angle” slider) and the centre can be translated either horizontally ("X center” slider) or
vertically ("Y center” slider) to adjust the cases to the 2D space. The background colour of each class and their respective glyphs can be
customised with the “Classes” panel at the bottom right of the screen.
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Version 2.0. Released in July 2007. This version
included for the first time a classifier for the long TE
spectra of the INTERPRET set, in addition to the short
TE spectra classifier. It also used the term “case” to des-
ignate the association of the short and long TE MR
Spectra obtained from the same VOI during the same
MR study. The “Manual Overview” was adapted for its
use with long TE spectra. The selected case was kept
selected even if the user changed between different
views (classifier overview or manual overview) or classi-
fiers (short or long TE). In this version, the DMS was
finally incorporated into the DSS and the user could
work with his/her own cases directly from the raw data
files as it has been described previosly. A further quality
control of the processed MR spectra was performed and
some of them were reprocessed with the JMRUI+JDMS
pipeline. Classifiers at short and long TE were retrained
with an in-house MatLab® pipeline, essentially equal to
what will be described for version 3.0. The only differ-
ence was that the number of variables of the classifier
was set to 13 both for the short and the long TE classi-
fiers and that no independent test set was used to vali-
date classifiers’ performance.
Version 3.0. Released in September 2009. Changes
with respect to previous versions: The system changed
the storage strategy and contains an embedded database.
The user can store his/her cases permanently. Different
users can share “Case Notes” turning the system into a
knowledge base. The look and feel of the GUI has been
made fully customisable with respect to colours and
glyphs. The following new concepts have been incorpo-
rated: possibility of having different data sets, case label
by superclasses, classifier boundaries, user profiles, mul-
tiple classifiers and concatenated short and long TE
spectra on display and for building the classifiers. The
embedded database allows semiautomatic incorporation
of new datasets and classifiers without requiring any
further change into the GUI. Two more releases, 3.0.1.
(November 2009) and 3.0.2 (January 2010) account for
minor Windows Vista and 7 compatibility issues and
the DMS distribution, respectively.
Discussion
In this work we have shown how the initial INTERPRET
DSS was improved in several aspects while maintaining
the same look and feel. The improvements have been
gradually released in successive versions in the 2003-
2010 period, and can be categorised in three different
aspects: GUI enhancements; increased analysis capabil-
ities, and data quality and assessment checks.
Although several published approaches to the auto-
mated characterisation of MR spectra from abnormal
brain masses do exist [21-24], especially for multi-voxel
spectra, the INTERPRET DSS is, to our knowledge, the
only system that helps users analyse and classify their
own SV MR spectral data obtained at a field strength of
1.5 T. As in the initial systems’ conception, the software
does not provide an answer, but is aimed to help users
extract information from data, basically through com-
parison with similar cases. The comparison is directed
by the classifiers available. In contrast to the first ver-
sion, where only one classifier had been implemented,
the current one incorporates seven classifiers, account-
ing as well for several acquisition conditions. In this
regard, potential users of the system can also check pre-
vious literature on advice for choosing the most suitable
classifiers [25-27].
There is currently no consensus on the best TE for
classifying among brain tumours, some previous work
has shown [13,17] that short TE could be better for its
improved sensitivity to mobile lipids and heavily J-
modulated or short T2 compounds. In any case, the use
of the information from both TEs should also be evalu-
ated, and the system now provides the tool for this. The
introduction of classifiers for distinguishing whether a
brain mass is a tumour or not can be of interest in
some situations where the MRI is inconclusive [14].
Although the classifiers available have been evaluated
with independent test sets, the system as a whole may
benefit from an extensive clinical evaluation that ideally
would have to consider the following aspects:
1st) Usability. Whether the different degrees of medi-
cal or spectroscopic expertise influence how the system
is used and the conclusions that are extracted. Now,
users can choose among 7 classifiers and can also make
their own overviews. The system does not recommend
any classifier over another. Therefore, which one is to
be chosen? Should this vary with the clinical problem
addressed? Is the radiologist the one suggesting the clas-
sifiers to be used? Is the medical physicist or the radiol-
ogy technologist the one to decide how to make the
analysis?
2nd) Transferrability. Whether the classifiers provided
have similar performances when challenged with cases
from different clinical centres.
3rd) Classification performance limits. Whether the
classifiers provided fulfil the range of clinical questions
in abnormal brain mass characterisation. Furthermore,
there are several discriminations with clinical impor-
tance that have not been accounted for in any of the
DSS versions: Glioblastomas vs. Metastases, or Lympho-
mas vs. Other WHO grade IV tumours. The Glioblas-
toma vs. Metastasis discrimination problem has been
previously attempted [4,15,28,29], but results are not
easily generalisable and multivoxel spectroscopy has
been previously shown to be better than SV at this dis-
tinction [30]. The system is now prepared to incorporate
new classifiers and databases, therefore from version 3.0
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onwards the introduction of a new classifier and its
associated database should not be a problem as long as
it could be viewable through a 2D or even a 3D plot.
There is one additional limitation of the system that will
also need to be addressed in the future: Since 2006,
users of previous DSS versions have been declaring
interest in the possibility to enter and analyse MRS data
acquired with 3 T scanners, which are becoming more
and more frequent. The SC2DSS tool will allow to over-
come this limitation. However, it remains to be tested
whether the current INTERPRET canonical format of
512 points adequately represents the information con-
tained in the raw data from different manufacturers and
equally importantly, whether classifiers generated at 1.5
T perform well with 3 T data, and under which circum-
stances e.g. for which classification questions.
The successive versions of this system have been dis-
tributed to some 150 centres throughout the world. It is
expected that the use of version 3.0 and feedback from
users will help to shape and further improve future ver-
sions of the INTERPRET DSS.
Conclusions
The INTERPRET DSS 3.0 allows radiologists, medical
physicists, biochemists or generally speaking, any person
with a minimum knowledge of what an MR spectrum is,
to enter their own SV raw data, acquired at 1.5 T, and
to analyse them. The system is expected to help in the
categorisation of MRS from any abnormal brain mass.
Availability and requirements
Project name: INTERPRET Decision Support System
version 3.
Project home page: http://gabrmn.uab.es/dss.
Operating system(s): Windows XP, Vista 7.
Programming language: Fortran, C, C++, Java.
Other requirements: Java 1.5 or higher.
License: With disclaimer signature.
Any restrictions to use by non-academics: All users
need the license agreement.
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